View all newsletters
Receive our newsletter – data, insights and analysis delivered to you


Contract Pharmaceutical Development Services and Commercial Manufacturing

With a commitment to quality, scientific excellence and exceptional customer experiences, Patheon is the world's leading provider of contract pharmaceutical development services and commercial manufacturing.

US Headquarters,
4721 Emperor Blvd Suite 200,
Durham, NC 27703-8580,
United States of America
Patheon offers its customers access to a broad range of royalty-free dosage technologies and scientific expertise.

Patheon specialises in pharmaceutical development and manufacturing services.

Active pharmaceutical ingredients (API) for the pharmaceutical sector

Patheon provides an integrated and customizable range of active pharmaceutical ingredients (API) and finished drug product services, including formulation development, clinical and commercial-scale manufacturing, packaging, and lifecycle management.

The company’s services address small and large molecule biological drugs.

Patheon is an end-to-end integrated provider, which combines scientific and regulatory expertise and specialised capabilities. This provides clients with a single outsourced provider to address complex development and manufacturing challenges.

Early Development: We deploy advance technologies for characterization of drug substances, evaluation of formulation options and to set a clear path to in-vitro, preclinical and first-in-man studies.
Late Development: Expertise in all stages of development makes us uniquely capable of developing formulations and processes that ensure future manufacturability and repeatable quality.
Commercial Supply: Consistent on-time delivery, dependable quality and depth of expertise have made Patheon the industry’s leading supplier of contract commercial supply services.
Solid Dose Forms: Patheon offers a remarkable range of conventional solid dose forms as well as specialized combinations and controlled release technologies.
Sterile Products: We offer extensive sterile product development and commercial manufacturing capabilities, including world-class expertise in lyophilization and ready-to-use dose formats.
High Potency: Customers with highly potent compounds, such as hormones, get the same flexibility, quality, expertise and breadth of resources as all Patheon customers.
Biologics: With the experience of more than 94 biologic development projects, we offer a broad range of capabilities and resources – often within a single site – to achieve the most effective formulation.
Quick to Clinic™: For a fixed price and guaranteed four-month timeline, you can have a solid dose molecule formulated into clinical material for first-in-man (Phase I) studies.
Patheon Certified Consultants: CMC guidance, transaction diligence support, and decision acceleration from top independent consultants behind over 200 products and 2,000 IND submissions.

Patheon specialises in leading product development services and commercial-scale product manufacturing.

Development and manufacturing solutions

Patheon transforms the pharmaceutical supply chain model with innovative, flexible, and customised end-to-end development, as well as manufacturing solutions that reduce complexity and shorten time-to-market.

Clients gain access to a wide range of drug substances, pharmaceutical development, and drug product solutions for large and small molecules, including an array of oral solid, sterile, and softgel dosage forms.

This provides flexibility to choose the most appropriate chemistry, manufacturing, and controls (CMC) technologies with the confidence that the programme will be delivered on time.

The company employs new business models to help clients simplify their supply chain management activities in an increasingly complex drug development industry.

Drug substance and drug product services

Patheon is organized into three distinct business units, drug substance services (DSS), pharmaceutical development services (PDS), and drug product services (DPS).

DSS is one of the top three outsourced manufacturers of highly complex biological drug substance produced in four biological API facilities. These sites are positioned to serve 70% of the market.

Patheon provides complex small molecule APIs and flexible outsourced manufacturing solutions for large molecule biologic APIs from early development through to commercial-scale production.

PDS Patheon is a leading global provider of formulation services. The company’s capabilities span the full breadth of advanced scientific services, including discovery, regulatory approval and formulation development across 40 dosage forms, as well as analytical services and life-cycle management.

DPS Patheon has developed and manufactured 20% of the top 100 drugs and 75% of the dosage forms on the market over the past decade.

Patheon has 8,700 employees, including more than 600 scientists in 25 locations in Europe, North America, Australia, and Asia.

The company has provided development and manufacturing services for approximately 400 clients for more than 700 products and molecules.

Through Patheon’s integrated global network of facilities, clients needs are met, which includes expertise to pharmaceutical, biotechnology and specialty pharmaceutical companies. This expertise helps clients bring drug candidates, including pre-clinical stages such as clinical trials and commercial supply.

Patheon provides a comprehensive suite of capabilities that addresses 75% of dosage forms with expertise and specialised capacity in high-potency, controlled substances, low-solubility, sterile, modified release, and softgel technologies.

Patheon OneSource

Patheon OneSource is an end-to-end development product that is simple to use, quick, and high-quality.

  • OneSource streamlines supply chain activities and a project manager is assigned to serve as a single point of contact for overseeing both APIs and finished products, as well as offering customers a flexible contracting process.
  • The offering can save up to 12 weeks, which is a significant improvement on the industry standard of a 15-month development cycle. In addition, Patheon can reduce redundancies through measures such as combined analytical activities, scientific collaboration, and parallel processing.
  • OneSource co-ordinates joint teams to collaborate and provide input early on in the process. Patheon has established a single harmonized quality system across its global network, ensuring it adheres to its proven track record with Right First Time and On Time Delivery, drawn on years of experience with large and small molecule APIs.

Patheon offers four specific flexible manufacturing options which are the dedicated asset model, fractional ownership model, flexible network access and the ‘condominium model.’

The company provides pharmaceutical and biotechnology companies with direct access to the expertise, quality, and full range of small or large molecule drug substance and solid and sterile dosage forms including:

  • Small molecule APIs and cGMP production
  • Process development, generic APIs and pharmaceutical intermediates portfolio
  • Biologics, mammalian cGMP and non cGMP manufacturing
  • Process and early development
  • Drug substance characterization
  • Analytical and formulation development and validation
  • Clinical trial material manufacturing
  • Late development and process and method development
  • Release and stability testing
  • Regulatory support and lifecycle management services
  • Commercial manufacturing and packaging
  • Tech transfer/scale-up management
  • Risk mitigation services

Solid and Sterile Dose Forms

All pharmaceutical products have unique manufacturing challenges and the available options need to precisely meet these needs.


Patheon OneSource speeds up the development timelines of large and small molecule discoveries.


This video is about the services that Patheon provides.


This video is about the services that Patheon provides.

Parallel Screening, European Pharmaceutical Contractor

Improving the bioavailability of poorly soluble new chemical entities is a leading challenge in drug development. Parallel screening is a cost-effective concept for selecting a suitable drug delivery system to enhance the chance of achieving the bioavailability target in the clinic.

Formulation Strategies for Poorly Soluble Drugs

With the advent of combinatorial chemistry and high throughput screening, the number of poorly water soluble drug candidates has dramatically increased. The "drugability" of new chemical entities (NCEs) and life-cycle management of marketed pharmaceutical products are becoming more challenging.

Patheon Milton Park Facility

Patheon is one of the largest contract drug development and manufacturing service providers in the world. To meet the in

A Cure for Pharmaceutical Supply Chain Complexity

The complexity of drug product supply chains has increased over the last few years mainly due to the development of more complex chemical molecules with more synthesis steps, increasing suppliers and geographies in the chain, and reduced average production volumes.

2 February 2016

Patheon Unveils New Brand and Identity

Patheon has unveiled its new brand identity, reflecting the company's leadership position in the pharmaceutical services industry, and the difference it makes in the lives of patients.

29 September 2015

Patheon Announces Biologics Deal with Inhibrx

Patheon has entered a development contract with Inhibrx, a biologic immunotherapeutic company focused on high, unmet medical needs in oncology, infectious disease and inflammatory conditions.

15 June 2015

Patheon Closes Acquisition of IRIX Pharmaceuticals

Patheon has closed the acquisition of IRIX Pharmaceuticals, a company that specialises in making difficult to manufacture active pharmaceutical ingredients (API) for drugs from early and late development, through to commercial launch.

1 April 2015

DPx Holdings BV Secures Purchase of Gallus BioPharmaceuticals

DPx Holdings BV has announced that it has reached a definitive agreement to buy all the shares of Gallus BioPharmaceuticals, a leading contract manufacturing company specialising in biologics and current portfolio company of Ridgemont Equity Partners.

27 August 2014

Patheon Announces Launch of Updated Quick to Clinic Programme

Patheon, the pharmaceutical services business owned by DPx Holdings B.V, announced the launch of its updated programme Quick to Clinic™, making it the only CDMO to offer customers an accelerated 12-week clinical trial material programme with stability data, with a variety of flexible dosage forms.

26 August 2014

Get Expert Opinions from Patheon

Patheon gives global pharmaceutical, biotechnology and specialty pharmaceutical companies access to the resources and expertise to bring drug candidates from preclinical stages through clinical trials to commercial supply.

19 August 2014

2014 DCAT Week

Patheon is to attend the 2014 DCAT Week from 10-13 March.

7 March 2014

Patheon’s High-Potency Capabilities Results in Expanded Capacity for European Facilities

Patheon is to specialise in high-potency at the company's Milton Park, UK, facility. Investment in early development capabilities in Europe means increased capacity for handling highly potent compounds in the early pharmaceutical development phases in the UK and then feeding into the later stage and commercialisation capabilities at a site in Bourgoin, France.

22 January 2014

Free Patheon White Papers Available for Download

Patheon is a leading provider of contract pharmaceutical development services and commercial manufacturing. Patheon has three white papers available for download free of charge from Pharmaceutical Technology.

16 July 2013

Patheon to Showcase High Potency Capabilities at Upcoming Tradeshows

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that the company will showcase its high potency capabilities at the 2013 BIO International Convention in Chicago, Illinois on April 22 - 25, 2013, as well as at INTERPHEX 2013 in New York City on April 23 - 25, 2013.

22 April 2013

Patheon Completes Acquisition of Banner Pharmacaps

Patheon, a leading provider of contract development and manufacturing services to the global pharmaceutical industry, today announced that it has completed its acquisition of Banner Pharmacaps (Banner), a specialty pharmaceutical business dedicated to the research, development and manufacturing of unique gelatin-based dosage forms.

17 December 2012


US Headquarters
4721 Emperor Blvd Suite 200
Durham, NC 27703-8580
United States of America

Patheon UK Limited European Headquarters and Swindon Operations (SND)

Kingfisher Drive
Covingham, Swindon
Wiltshire SN3 5BZ
United Kingdom

Patheon K.K. Japan Office

7F Wakamatsu Building, 3-3-6
Nihonbashi Hon-cho, Chuo-ku,
Tokyo 103-0023

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology